<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gourh P</submitter><funding>NCATS NIH HHS</funding><funding>NIAMS NIH HHS</funding><pagination>552-562</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6955366</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>117(1)</volume><pubmed_abstract>Systemic sclerosis (SSc) is a clinically heterogeneous autoimmune disease characterized by mutually exclusive autoantibodies directed against distinct nuclear antigens. We examined &lt;i>HLA&lt;/i> associations in SSc and its autoantibody subsets in a large, newly recruited African American (AA) cohort and among European Americans (EA). In the AA population, the African ancestry-predominant &lt;i>HLA-DRB1&lt;/i>*&lt;i>08:04&lt;/i> and &lt;i>HLA-DRB1&lt;/i>*&lt;i>11:02&lt;/i> alleles were associated with overall SSc risk, and the &lt;i>HLA-DRB1&lt;/i>*&lt;i>08:04&lt;/i> allele was strongly associated with the severe antifibrillarin (AFA) antibody subset of SSc (odds ratio = 7.4). These African ancestry-predominant alleles may help explain the increased frequency and severity of SSc among the AA population. In the EA population, the</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>&lt;i>HLA&lt;/i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.</pubmed_title><pmcid>PMC6955366</pmcid><funding_grant_id>K23 AR075112</funding_grant_id><funding_grant_id>T32 AR048522</funding_grant_id><funding_grant_id>UL1 TR003167</funding_grant_id><funding_grant_id>K08 AR070285</funding_grant_id><funding_grant_id>P60 AR062755</funding_grant_id><funding_grant_id>P30 AR070254</funding_grant_id><funding_grant_id>P30 AR070155</funding_grant_id><funding_grant_id>K01 AR067280</funding_grant_id><pubmed_authors>Schiopu E</pubmed_authors><pubmed_authors>Silver RM</pubmed_authors><pubmed_authors>Alexander T</pubmed_authors><pubmed_authors>Khanna D</pubmed_authors><pubmed_authors>Shah AA</pubmed_authors><pubmed_authors>Shriner D</pubmed_authors><pubmed_authors>Korman BD</pubmed_authors><pubmed_authors>Bernstein EJ</pubmed_authors><pubmed_authors>Hsu V</pubmed_authors><pubmed_authors>Remmers EF</pubmed_authors><pubmed_authors>Boyden SE</pubmed_authors><pubmed_authors>Shanmugam VK</pubmed_authors><pubmed_authors>Bentley AR</pubmed_authors><pubmed_authors>Derk CT</pubmed_authors><pubmed_authors>Kafaja S</pubmed_authors><pubmed_authors>Mayes MD</pubmed_authors><pubmed_authors>Boin F</pubmed_authors><pubmed_authors>Mullikin JC</pubmed_authors><pubmed_authors>Domsic RT</pubmed_authors><pubmed_authors>Varga J</pubmed_authors><pubmed_authors>Kolstad KD</pubmed_authors><pubmed_authors>Kastner DL</pubmed_authors><pubmed_authors>Goldberg A</pubmed_authors><pubmed_authors>Criswell LA</pubmed_authors><pubmed_authors>Safran SA</pubmed_authors><pubmed_authors>Chung L</pubmed_authors><pubmed_authors>Jan R</pubmed_authors><pubmed_authors>Wigley FM</pubmed_authors><pubmed_authors>Steen VD</pubmed_authors><pubmed_authors>Ramos PS</pubmed_authors><pubmed_authors>Rotimi C</pubmed_authors><pubmed_authors>Gladue H</pubmed_authors><pubmed_authors>Saketkoo LA</pubmed_authors><pubmed_authors>Bridges SL</pubmed_authors><pubmed_authors>Trojanowski M</pubmed_authors><pubmed_authors>Adeyemo A</pubmed_authors><pubmed_authors>Morgan ND</pubmed_authors><pubmed_authors>Gourh P</pubmed_authors><pubmed_authors>Chandrasekharappa SC</pubmed_authors><pubmed_authors>Doumatey A</pubmed_authors><pubmed_authors>Steinbach PJ</pubmed_authors><pubmed_authors>Gordon JK</pubmed_authors><pubmed_authors>Kron B</pubmed_authors><pubmed_authors>Medsger TA</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>HLA&lt;/i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.</name><description>Systemic sclerosis (SSc) is a clinically heterogeneous autoimmune disease characterized by mutually exclusive autoantibodies directed against distinct nuclear antigens. We examined &lt;i>HLA&lt;/i> associations in SSc and its autoantibody subsets in a large, newly recruited African American (AA) cohort and among European Americans (EA). In the AA population, the African ancestry-predominant &lt;i>HLA-DRB1&lt;/i>*&lt;i>08:04&lt;/i> and &lt;i>HLA-DRB1&lt;/i>*&lt;i>11:02&lt;/i> alleles were associated with overall SSc risk, and the &lt;i>HLA-DRB1&lt;/i>*&lt;i>08:04&lt;/i> allele was strongly associated with the severe antifibrillarin (AFA) antibody subset of SSc (odds ratio = 7.4). These African ancestry-predominant alleles may help explain the increased frequency and severity of SSc among the AA population. In the EA population, the</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jan</publication><modification>2026-05-07T07:48:15.294Z</modification><creation>2020-05-22T07:54:43Z</creation></dates><accession>S-EPMC6955366</accession><cross_references><pubmed>31871193</pubmed><doi>10.1073/pnas.1906593116</doi></cross_references></HashMap>